Monika Długosz‐Danecka

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Stephen M. Ansell, John Radford, Joseph M. Connors et al. · New England Journal of Medicine · 2022 · 296 citations · Full text

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors et al. · The Lancet Haematology · 2021 · 153 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent <i>CARD11</i> mutations

Chenglin Wu, Noel F.C.C. de Miranda, Longyun Chen et al. · Oncotarget · 2016 · 135 citations · Full text

Genetics, Immunology, Pathology +21

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

Jason J. Luke, Manish R. Patel, George R. Blumenschein et al. · Nature Medicine · 2023 · 111 citations · Full text

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

David J. Straus, Monika Długosz‐Danecka, Sergey Alekseev et al. · Blood · 2020 · 109 citations · Full text